<DOC>
	<DOC>NCT01830140</DOC>
	<brief_summary>This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).</brief_summary>
	<brief_title>A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Diagnosis of glaucoma or ocular hypertension Active ocular disease other than glaucoma or ocular hypertension Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>